Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


The article discusses the choice of anticoagulant in different patterns of acute coronary syndrome (ACS). According to current recommendations three groups of agents are used as anticoagulants in ACS: unfractionated heparin (UFH) and low molecular weight heparin (LMWH), fondaparinux, and bivalirudin. UFH was the main parenteral anticoagulant therapy for ACS for several decades, including percutaneous coronary interventions, but a number of limitations and side effects of the drug contributed to the emergence of new anticoagulants with lower molecular weight. Among the LMWH, which have a higher bioavailability and significant convenience of administration, only enoxaparin has significant clinical advantage over UFH considering the prognosis for patients with ACS. At the same time throughout the period of ACS, including invasive procedures, change of heparin products is extremely undesirable, since switching from enoxaparin to UFH and vice versa, not only reduces the effectiveness of the treatment, but also increases the risk of bleeding. Fondaparinux has optimal efficacy/safety profile in ACS with no ST elevation, regardless of the chosen tactics. If it is unavailable, enoxaparin or UFH may be an alternative. Bivalirudin is the optimal alternative to UFH in combination with GP IIb/IIIa platelet receptor blockers in case of invasive treatment strategy. In patients with impaired renal function with glomerular filtration rate (GFR)<30 mL/min/1.73m2 enoxaparin dose should be reduced to 1 mg/kg, 1 time a day, with GFR <15 mL/min/1.73m2 the drug is contraindicated. Fondaparinux safety is superior to enoxaparin in patients with chronic kidney disease, however the drug is not recommended in GFR<20 ml/min/1.73m2. In this case UFH should be preferred due to the ease of monitoring anticoagulant activity and the ability to quickly neutralize its activity in the case of bleeding.

About the Authors

E. A. Smirnova
Regional Clinical Cardiology Center; Ryazan State Medical University named after Academician I.P. Pavlov
Russian Federation

Elena A. Smirnova - MD, PhD, Head of Cardiology Department, Regional Clinical Cardiology Center; Associate Professor, Chair of Hospital Therapy, Ryazan State Medical University named after Academician I.P. Pavlov. 

Stroykova ul. 96, Ryazan, 390026 

S. S. Yakushin
Ryazan State Medical University named after Academician I.P. Pavlov
Russian Federation
Sergey S. Yakushin - MD, PhD, Professor, Head of Chair of Hospital Therapy


1. McLean J. The thromboplastin action of cephalin. American Journal of Physiology.1916;41:250-7.

2. Hirsh J., Anand S., Halperin J., Fuster V. Guide to Anticoagulant Therapy: Heparin: A Statement for Healthcare Professionals from the American Heart Association. Circulation. 2001;103:2994-3018.

3. Cohen M., Demers C., Gurfinkel E., et al. A comparison of low-molecular-weight heрarin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997;337:447-52.

4. Goodman S., Cohen M., Bigonzi F., et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: 1-year results of the ESSENCE Study. JACC. 2000;36:493-698.

5. Antman E.M., McCabe C.H., Gurfinkel E.P., et al. Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non-Q-Wave Myocardial Infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B Trial. Circulation. 1999;100:1593-601.

6. Antman E.M., Cohen M., Radley D., et al. Assessment of the Treatment Effect of Enoxaparin for Unstable Angina/Non-Q-Wave Myocardial Infarction. TIMI 11B-ESSENCE Meta-Analysis. Circulation. 1999;100:1602-8.

7. Antman Е., Cohen M., McCabe C., et al. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up TIMI 11B and ESSENCE. Eur Heart J. 2002;23:308-14.

8. Cohen M., Theroux P., Borzak S., et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: The ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin. Am Heart J. 2002;144:470-7.

9. Goodman S., Fitchett D., Armstrong P., et al. Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial Investigators. Randomized Evaluation of the Safety and Efficacy of Enoxaparin Versus Unfractionated Heparin in High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Receiving the Glycoprotein IIb/IIIa Inhibitor Eptifibatide. Circulation. 2003;107:238-44.

10. Blazing M., de Lemos J., White H., et al. For the A to Z Investigators. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA. 2004;292:55-64.

11. Ferguson J., Califf R., Antman E., et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292(1):45-54.

12. Murphy S., Gibson C., Morrow D., et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a metaanalysis. Eur Heart J. 2007;28(17):2077-86.

13. Cohen M., Mahaffey K., Pieper K., et al. A Subgroup Analysis of the Impact of Prerandomization Antithrombin Therapy on Outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2006;48(7):1346-54.

14. Petersen J.L., Mahaffey K.W., Hasselblad V., et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004;292(1):89-96.

15. Drouet L., BalditSollier C., Martin J. Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACKon to ENOXaparin (STACKENOX) study. Am Heart J. 2009;158:177-84.

16. Syrov A.V., Zyryanov S.K., Belousov Yu.B. Comparative pharmacoeconomic assessment of enoxaparin and unfractionated heparin in non-ST-segment elevation acute coronary syndrome. Rossijskij Kardiologicheskij Zhurnal. 2010; 2 (82): 59-66. (In Russ.) [Сыров А.В., Зырянов С.К., Белоусов Ю.Б. Сравнительная фармакоэкономическая оценка эноксапарина и нефракционированного гепарина при остром коронарном синдроме без подъема сегмента ST. Российский Кардиологический Журнал. 2010; 2 (82): 59-66].

17. Gowthami M., Thomas L. Heparin-Induced Thrombocytopenia. N Engl J Med. 2006;355:809-17.

18. LaPointe N.M., Chen A.Y., Alexander K.P., et al. Enoxaparin Dosing and Associated Risk of In-Hospital Bleeding and Death in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. Arch Intern Med. 2007;167:14:1539-44.

19. Roffi M., Patrono C., Collet J., et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315.

20. Simoons M.L., Bobbink I.W., Boland J., et al. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: The Pentasaccharide in Unstable Angina (PENTUA) study. Am Coll Cardiol. 2004;43:2183-90.

21. Mehta S.R., Steg P.G., Granger C.B., et al. Randomized, Blinded Trial Comparing Fondaparinux With Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention. Arixtra Study in Percutaneous Coronary Intervention: A Randomized Evaluation (ASPIRE) Pilot Trial. Circulation. 2005;22:111:1390-7.

22. Yusuf S., Phil D., Mehta S., et al. The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS-5). N Engl J Med. 2006;354;1464-6.

23. Stone G.W., McLaurin B.T., Cox D.A., et al. Bivalirudin for Patients with Acute Coronary Syndromes. ACUITY Investigators. N Engl J Med. 2006;355:2203-16.

24. Collet J.P., Montalescot G., Lison L., et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation. 2001; 103: 658-63.

25. Martin J.L., Fry E.T., Sanderink G.J., et al. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: the pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv. 2004;61:163-70.

26. Silvain J., Beygui F., Barthelemy O., et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ. 2012;344:553.

27. 2014 ACC/AHA Guideline for the management of patients with non-ST-elevation Acute Coronary Syndromes: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(24):2645-87.

28. Bellil S, Yakushin SS, Aksent'ev SB, Yunevich DS. Comparative prognosis in elderly and senile patients with Q-myocardial infarction during 12 months of observation depending on different schemes of reperfusion therapy. Rossijskij Mediko-Biologicheskij Vestnik im. Akademika I.P. Pavlova. 2015;1:904. (In Russ.) [Беллил С., Якушин С.С., Аксентьев С.Б., Юневич Д.С. Сравнительный прогноз у больных пожилого и старческого возраста с перенесенным инфарктом миокарда с подъемом сегмента ST в течение 12 месяцев наблюдения в зависимости от различных схем реперфузионной терапии. Российский Медико-Биологический Вестник им. Академика И.П. Павлова. 2015;23(1):90-4].

29. Seliverstova D.V., Evsina O.V. Myocardial infarction of young patients: risk factors, course, clinic, management on the hospital treatment stage. Nauka Molodyh - Eruditio Juvenium. 2013;4: 106-11. (In Russ.) [Селиверстова Д.В., Евсина О.В. Инфаркт миокарда у пациентов молодого возраста: факторы риска, течение, клиника, ведение на госпитальном этапе. Наука Молодых - Eruditio Juvenium. 2013;4:106-11].

30. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal. 2012;33:2569-619.

31. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association. Task Force on Practice Guidelines. Circulation. 2013;127:362-425.

32. Brener S.J., Moliterno D.J., Lincoff A.M., et al. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of recent randomized clinical trials of percutaneous coronary intervention. Circulation. 2004;110:994-8.

33. Xiao Z., Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecularweight heparin and with a direct thrombin inhibitor. Circulation. 1998;97:251-6.

34. Montalescot G., Zeymer U., Silvain J., et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST -elevation myocardial infarction: the international randomized open-label ATOLL trial. The Lancet. 2011;378:693-703.

35. Dangas G.D., Caixeta A., Mehran R., et al. Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI). Trial Investigators. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation. 2011;123:1745-56.

36. Yusuf S., Mehta S.R., Chrolavicius S., et al. Effects of Fondaparinux on Mortality and Reinfarction in Patients With Acute ST-Segment Elevation Myocardial Infarction. The OASIS-6 Randomized Trial. JAMA. 2006;295:1519-30.

37. Antman E.M., Morrow D.A., McCabe C.H., et al. Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction. N Engl J Med. 2006;354:1477-88.

38. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001;358:605-13.

39. Armstrong P.W., Gershlick A., Goldstein P., et al., on behalf of the STREAM Steering Committee. The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. Am Heart J. 2010;160: 30-5.

For citation:

Smirnova E.A., Yakushin S.S. THE USE OF ENOXAPARIN IN ACUTE CORONARY SYNDROME. Rational Pharmacotherapy in Cardiology. 2016;12(6):749-757. (In Russ.)

Views: 972

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)